Abstract
Imatinib, a first-line treatment for chronic myelogenous leukemia, presents significant interindividual pharmacokinetic variability. The correlation between the plasma exposure of Imatinib and its pharmacological effects makes this drug a good candidate for pharmacological therapeutic monitoring in addition to the usual monitoring tests. We introduced monitoring of Imatinib in 27 patients suffering from chronic myelogenous leukemia. According to the dosage results, dosage adaptation recommendations were proposed to clinicians in patients outside the targeted therapeutic range. The goal was to achieve an optimal response to Imatinib, prevent its adverse effects and improve adherence to treatment.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
